On the other hand, we see an increase in risk-weighted assets up to the crisis, with a slight drop afterwards and the trend steadying since then. The deal will free up capital of some EUR 400 million, primarily by reducing risk-weighted assets by EUR 4.
The Heska Corporation is involved in biotechnical research for the development of vaccines and related diagnostic products for companion animals. The company manufactures health care products for dogs, cats, and horses and markets them to veterinarians.
We believe in collaboration, outstanding quality and customer relations and so does Hesco. This is a partnership that will significantly strengthen Betafenceâs high security growth strategy. Hescoâs strong reputation in key defence channels together with their existing relationships with major industry players will add value to our approach in shared key markets such as Oil and Gas, Energy and Government.